THE TOTALITY OF EVIDENCE SUPPORTING IVERMECTIN IN COVID-19



BASIC SCIENCE

- Ivermectin inhibits many viruses: West Nile, Dengue, Zika, SARS-COV1, SARS-COV2
- Ivermectin has multiple anti-inflammatory properties
- Ivermectin binds to SARS-COV2 and prevents entry and replication

PHARMACOLOGY

- Ivermectin is a safe drug prescribed BILLIONS of times
- On the WHO's list of essential medications
- Reactions and Side Effects are EXTREMELY RARE
- Effective tissue concentrations are easily reached with standard doses

CLINICAL EXPERIENCE

- Clinicians worldwide have reported consistent positive results in treatment of their covid-19 patients
- Large case series have reported EXTREMELY low rates of hospitalization and death
- Dominican Republic is one example with 3000 consecutive patients treated in the ER, 16 admissions, 1 death

OBSERVATIONAL CLINICAL TRIALS

- 31 Trials, including over 6800 patients (August 2021)
- Consistent, often LARGE Decreases in:
  - Transmission from person to person
  - Time to recovery
  - Hospital admissions, severe disease, and death



RANDOMIZED CLINICAL TRIALS

- 27 trials including over 3400 patients (August 2021)
- Results of the studies found:
  - LARGE reductions in mortality
  - Dose dependent reductions in time to viral clearance
  - More rapid clinical recovery

META-ANALYSES

- Putting the OCTs and RCTs data together:
- 63 trials 26,422 patients
- 52% - 91% reduction in mortality
- 3 days faster time to viral clearance
- 1.5 days faster time to clinical recovery



EPIDEMIOLOGIC STUDIES

Large Health Ministry "Test and Treat" Program studies report

- 88% reduction in death, 75% reduction in hospitalizations
- 75% reduction in hospitalization in over 50,000 patients (Mexico City, Mexico)
- 35% - 40% reduction in death, ICU, hospitalization (La Pampas, Argentina)
- Uttar Pradesh, India (pop. 241 million) eradicated COVID from the state with widespread, systematic use of ivermectin in prevention and treatment

FLCCC ALLIANCE

www.flccc.net